Stocksigma LogoStocksigma Logo

Symbiotec Pharmalab Board to Review Q2 FY27 Results on 5th Nov'26

Symbiotec Pharmalab Limited has scheduled its Board of Directors meeting for 5th Nov'26 to consider and approve the unaudited standalone and consolidated

Symbiotec Pharmalab Board to Review Q2 FY27 Results on 5th Nov'26

Symbiotec Pharmalab Ltd 路 Intimation 路 05 Nov 2026, 5:30 am

Symbiotec Pharmalab Board to Review Q2 FY27 Results on 5th Nov'26 Symbiotec Pharmalab Limited has scheduled its Board of Directors meeting for 5th Nov'26 to consider and approve the unaudited standalone and consolidated financial results for the quarter and half-year ended 30th Sep'26, alongside the Limited Review Report. In compliance with insider trading regulations, the company's trading window for dealing in its securities by designated persons and their immediate relatives remains closed until 48 hours following the official declaration of the financial results.

Original exchange filing (PDF)

More announcements from Symbiotec Pharmalab Ltd

All Symbiotec Pharmalab Ltd announcements